Most breast cancers were invasive ductal carcinoma (209, 90.9%) or ductal carcinoma in situ (19, 8.3%); 111 (48.3%) were luminal, 85 (37.0%) were TNBC, and 33 (14.3%) were HER2 positive (HER2+). Here, ERBB2 is linked to breast carcinoma.